Jefferies Names Possible Hedge Fund Short Targets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/16/2024
- S&P 500, Nasdaq extend record streak on renewed rate-cut hopes
- Walmart lifts full-year sales and profit forecast, shares hit record high
- Cisco lifts annual revenue guidance after Q3 results top estimates
- Record high stocks bask in rate cut hopes
- Oil prices rise after US economic data raises rate cut expectations
- AMC Entertainment (AMC) entered into privately negotiated exchange agreements
- Trade Desk (TTD), Magnite (MGNI) climb following report Netflix (NFLX) will launch an in-house advertising technology platform
- BMO Capital Reiterates Underperform Rating on Plug Power (PLUG)
- Crude Inventory Decreases by 2.5 Million Barrels: EIA
- Plug Power (PLUG) Announces Class 6 Fuel Cell Electric Truck Integration
- Midday movers: Walmart, Chubb and Trade Desk rise; Meta, GameStop fall
- After-hours movers: Cisco Systems and Chubb rise, and more
- Midday movers: AMC Entertainment, GameStop fall; Dell rises
- After-hours movers: AMC Entertainment, DLocal, Boot Barn, and more
- Midday movers: GameStop, AMC Entertainment rise; Alibaba falls
Biogen (BIIB) Reports FDA Approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
February 1, 2021 7:33 AM ESTBiogen Inc. (NASDAQ: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. This... More
RBC Capital Reiterates Sector Perform Rating on Pfizer (PFE)
February 1, 2021 6:49 AM ESTRBC Capital analyst Randall Stanicky reiterated a Sector Perform rating and $42.00 price target on Pfizer (NYSE: PFE) ahead of the company's 4Q earnings release. PFE is set to report 4Q results this Tuesday. Stanicky thinks the 4Q set up is relatively favorable on the back... More
Stifel Upgrades Biogen (BIIB) to Buy
January 29, 2021 8:48 AM ESTStifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $358.00 (from $258.00).
The analyst comments "Our initial reaction after the Aducanumab AdComm was that the path to FDA approval seems challenging. Since, Biogen management's... More
